Recent coverage of innovative research and development across the biopharma and medtech sectors.
READ NOWFeatured Stories
After Humira Biosimilars, Will It Be Groundhog Day For Stelara?
With ustekinumab biosimilars set to launch in Europe imminently and in the US early next year, the off-patent industry may be wondering whether it will be in for a rerun of its experiences with competition on Humira – or whether the landscape has changed sufficiently to allow for different pricing and uptake trends.
![](/-/media/editorial/in-vivo/2024/07/iv072024-unlocked.jpg?rev=0d88cb776392492683c9a08a518a2661&w=784&hash=EC204A552C41DDBAFE2D8175AFBF5E4C)
DISCO Pharma’s Surfaceome Technology Unlocks Novel Cancer-Selective Targets
Roman Thomas, co-founder and CEO of DISCO Pharmaceuticals, outlines how the company’s surfaceome technology could disrupt drug discovery in oncology.
![](/-/media/editorial/scrip/2024/06/sc2406_parexelexecutives_1200.jpg?rev=90c4f7ad5cb84d0eb3b39a697d560d5b&w=784&hash=E05F12082841FFAE6E0885475A53F564)
Parexel Execs On Obesity, AI And Data Trends
Parexel’s chief strategy officer Kushal Gohil, clinical EVP Stephen Pyke and India head Sanjay Vyas share thoughts on possible hurdles to, and the cascading impact of obesity treatments, GenAI progress and the opportunities and challenges of real-world data in India.
Latest Articles
![](/-/media/editorial/in-vivo/2024/07/iv072024-clinical-testing.jpg?rev=caa2c9779ebb461898ed25c6ccbf6789&w=350&hash=7D45FA7220154627F9C175C1C209DC76)
Examining The Antibody-Drug Conjugate Pipeline
An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs. The earlier stage pipeline boasts a range of mechanistic approaches.
![](/-/media/editorial/in-vivo/00-regular-feature-columns/iv2306_biobytes_1704195040_1200.jpg?rev=4d68bf81259a4222ba528f1e2daffa98&w=350&hash=8B9B54848237A4180426452250FCED68)
Formation Secures Huge Series D For AI Platform Growth
Biopharmaceutical venture capital fundraising is on the rise in 2024. In late June, Formation Bio secured a mega financing, raising $372m via a series D round led by a16z and Sanofi.
![](/-/media/editorial/scrip/2024/05/sc2405_alliance_shutterstock_1978811975_1200x675.jpg?rev=b2916b3a40054384ad4e6b6a3ebd73e2&w=350&hash=3DD897E04CE1AC5D8D972A944DC4F71D)
BIO Roundup: Deal-Making Tips And Tricks
Key insights from the recent the BIO International Convention in San Diego, US.
![](/-/media/editorial/in-vivo/2024/06/womens-healthphotomw202405010081.jpg?rev=7f5059306b2340478270b3c4a5dae5c6&w=350&hash=DD3F1452E08CCB237657F539664512AE)
Women’s Health Innovation: What Are We Waiting For?
An investigator, an investor and an inventor walk into the New York Stock Exchange, and it’s no joke. Women’s health is a fruitful investment with a clear path to financial return.
![](/-/media/editorial/in-vivo/2024/07/iv072024-unlocked.jpg?rev=0d88cb776392492683c9a08a518a2661&w=350&hash=F74F4C4E8F3491E3193E3D0C8D1F6D7A)
DISCO Pharma’s Surfaceome Technology Unlocks Novel Cancer-Selective Targets
Roman Thomas, co-founder and CEO of DISCO Pharmaceuticals, outlines how the company’s surfaceome technology could disrupt drug discovery in oncology.
![](/-/media/editorial/in-vivo/2024/07/iv0724_rwanda-malaria-trial-site_1200.jpg?rev=648b9db4098f49e3b5ba59ea69d0e686&w=350&hash=C52B193D1C7AAD74C32E7DF0393939AF)
Tackling The Challenge Of Malaria Clinical Trials In Africa
Novartis leads the fight against malaria, pioneering innovative studies in sub-Saharan Africa to combat parasite resistance to current antimalarials.
![](/-/media/editorial/scrip/2021/01/sc2101_esophageal_726148573_1200.jpg?rev=5ac988c787c04357a1d80b7ff9161101&w=350&hash=202352958B76F26022AE1CB211C101E5)
Lucid Diagnostics Seeks Clear Path To US Reimbursement For Esophageal Precancer Test
Lishan Aklog, CEO of New York-based Lucid Diagnostics, has a long-term vision to provide the paradigm of prevention-to-treatment care for esophageal cancer. In the short term, the company anticipates a favorable outcome from an upcoming pivotal Medicare assessment of its early screening technology.
![](/-/media/editorial/in-vivo/2024/07/iv072024-three-parallel-cars.jpg?rev=189b7a04ea4b4cd8ba5256b3b1169ebc&w=350&hash=29E4CAAA0C57346A2DD3BCBD8594C70E)
Exeliom’s Bacteria-Focused Approach To Immunotherapy
In Vivo sat down with Benjamin Hadida, CEO of Exeliom, at the 2024 BIO International Convention to discuss how the company is using its first-in-class drug candidate to improve therapeutic responsiveness in immuno-oncology, immuno-inflammation and rare disease.
![](/-/media/editorial/scrip/2024/06/sc2406_titans_of_pharma_2024_1200.jpg?rev=3f3b082c7b694da8a493a823e2c1c14f&w=350&hash=45BBF277DF407063ABB22BF05A8CB720)
Titans Of Pharma: J&J Back On Top For CEO Remuneration
J&J topped the league table for CEO pay in 2023, a position it has held for three of the four past years. Meanwhile, the two companies that arguably generated the most buzz in 2023 neatly depict the stark contrast between the US and Europe when it comes to executive remuneration.
![](/-/media/editorial/scrip/2024/06/sc2406_parexelexecutives_1200.jpg?rev=90c4f7ad5cb84d0eb3b39a697d560d5b&w=350&hash=9D5E08446735DE96B14F1C91D707102E)
Parexel Execs On Obesity, AI And Data Trends
Parexel’s chief strategy officer Kushal Gohil, clinical EVP Stephen Pyke and India head Sanjay Vyas share thoughts on possible hurdles to, and the cascading impact of obesity treatments, GenAI progress and the opportunities and challenges of real-world data in India.
![](/-/media/editorial/in-vivo/00-regular-feature-columns/iv2107_executives_on_the_move_2c3p31h_1200.jpg?rev=ebe75dc55ee2420f97b9a985d8b2153f&w=350&hash=0B48CBFE66D110F395C774CE1E198084)
Executives On The Move: June 2024
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
![](/-/media/editorial/in-vivo/2024/06/iv062024_puzzle-pieces-deals_shutterstock.png?rev=0923dc81d90749fc94a380c395276abc&w=350&hash=879F2AC4AA1431CBAAA4A855807DE94C)
VC Insights On Future Tech And Future Leaders
“I'm a strong believer in creating the right mix between young ambitious people and pairing them up with someone experienced,” says Jeroen Bakker, who is focused on biotech company creation at Seed Investments, Novo Holdings.
![](/-/media/editorial/generics/2024/07/gb2407_groundhog_2389414317_1200.jpg?rev=cbb8d4843783408dbc09f33a626b527d&w=350&hash=CAA30061F63ABBAB5BDB90DFF5DF137D)
After Humira Biosimilars, Will It Be Groundhog Day For Stelara?
With ustekinumab biosimilars set to launch in Europe imminently and in the US early next year, the off-patent industry may be wondering whether it will be in for a rerun of its experiences with competition on Humira – or whether the landscape has changed sufficiently to allow for different pricing and uptake trends.
![](/-/media/editorial/in-vivo/00-regular-feature-columns/iv2209_generic_podcast_1137167453_1200.jpg?rev=dea49d82ad2e442e9ee9752384cc8355&w=350&hash=A98BACA50E8DA6481065F88A0023A3E8)
Podcast: Navigating Challenges – The Changing Role Of Big Pharma
Stefan Woxström, senior vice president of AstraZeneca, Europe and Canada, discusses the growing challenges in the industry and addresses the role big pharma must adopt in resolving them.
![](/-/media/editorial/stock-images/anatomy/weight-scales-1200-shutterstock_1490713412.jpg?rev=2d91d0c95a2f41828521274e570e2a2a&w=350&hash=E0DF8C03C28EEA5164EF4E0193EA951B)
Why US Payers Aren’t Reimbursing Obesity Meds
Payers are restricting access to obesity drugs due to huge patient numbers and a wave of innovation in other areas
![](/-/media/editorial/stock-images/geographical/china_growth_422682037_1200.jpg?rev=0cd0f20334f04d158536a09a6374b94a&w=350&hash=1FF6C95660473B4E332CC27D8988762B)
China Market For Medtech: Opportunity Or Headache?
Medtech companies have typically seen a “mixed picture of growth” in China in the past year or two, but it is a market that requires ongoing commitment, a panel of experts argued at the MedTech Forum 2024.
![](/-/media/editorial/in-vivo/2024/07/e-in-esg-final-copy-image-iv_2445711475_1200.jpg?rev=708889abd34a4dfcaa3cc9f9090ff350&w=350&hash=B06B58E4167FEF53F6889DA0E6321F10)
Medtechs Are Fully Engaged In Climate Change: ‘They Have No Choice’
The E in ESG: SUDs, reuse, disposables, refurbishing, reprocessed devices? Multiple panelists at the 2024 MedTech Forum addressed the role medtech manufacturers should have in the climate change challenge.
![](/-/media/editorial/in-vivo/00-regular-feature-columns/iv2107_qstats_pd0r88_1200_option1.jpg?rev=4f0d57fbbcec44ba9c4585aa59bcac30&w=350&hash=4D37078A8EA47372550D57C71A33D1DE)
Financing Quarterly Statistics, Q2 2024
During Q2, biopharmas brought in an aggregate $22.8bn in financing and device company fundraising totaled $2.7bn; while in vitro diagnostic firms and research tools players raised $1.2m.
![](/-/media/editorial/in-vivo/00-regular-feature-columns/iv2104_dealmaking_2e1pd03_1200.png?rev=fff34a1c8de946b2ae4c0beef505c85a&w=350&hash=5D293C74D34931D22EE105DA41055090)
Deals Shaping The Industry, June 2024
An interactive look at pharma, medtech and diagnostics deals made during June 2024. Data courtesy of Biomedtracker.
![](/-/media/editorial/in-vivo/00-regular-feature-columns/iv2107_dealsindepth_2e1ajgj_1200.png?rev=2974b8beac084189a9de2564d325bd02&w=350&hash=E7CD08A5026BD699D56277D9C27EAAB6)
Deals in Depth: June 2024
Four $1bn+ alliances were penned in June. In the top alliance by deal value, Ascidian Therapeutics signed an agreement with Roche for the discovery and development of RNA exon editing therapeutics targeting neurological diseases. Roche received exclusive rights to Ascidian's RNA exon editing technology for undisclosed targets. Ascidian will conduct discovery and certain preclinical activities in collaboration with Roche, which will be responsible for certain preclinical activities, and further clinical development, manufacturing, and commercialization. Ascidian will receive an up-front payment of $42m as well as up to $1.8bn in research, clinical, and commercial milestone payments, as well as sales royalties.
Medtechs Are Fully Engaged In Climate Change: ‘They Have No Choice’
The E in ESG: SUDs, reuse, disposables, refurbishing, reprocessed devices? Multiple panelists at the 2024 MedTech Forum addressed the role medtech manufacturers should have in the climate change challenge.
Financing Quarterly Statistics, Q2 2024
During Q2, biopharmas brought in an aggregate $22.8bn in financing and device company fundraising totaled $2.7bn; while in vitro diagnostic firms and research tools players raised $1.2m.
Examining The Antibody-Drug Conjugate Pipeline
An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs. The earlier stage pipeline boasts a range of mechanistic approaches.
Titans Of Pharma: J&J Back On Top For CEO Remuneration
J&J topped the league table for CEO pay in 2023, a position it has held for three of the four past years. Meanwhile, the two companies that arguably generated the most buzz in 2023 neatly depict the stark contrast between the US and Europe when it comes to executive remuneration.
Tackling The Challenge Of Malaria Clinical Trials In Africa
Novartis leads the fight against malaria, pioneering innovative studies in sub-Saharan Africa to combat parasite resistance to current antimalarials.
After Humira Biosimilars, Will It Be Groundhog Day For Stelara?
With ustekinumab biosimilars set to launch in Europe imminently and in the US early next year, the off-patent industry may be wondering whether it will be in for a rerun of its experiences with competition on Humira – or whether the landscape has changed sufficiently to allow for different pricing and uptake trends.
Deals Shaping The Industry, June 2024
An interactive look at pharma, medtech and diagnostics deals made during June 2024. Data courtesy of Biomedtracker.
Podcast: Improving Communication – The Relationship Between Biotech And Pharma
Ali Pashazadeh, CEO, chair and founder of Treehill Partners discusses the need for increased communication between biotech and biopharma.
Deals in Depth: June 2024
Four $1bn+ alliances were penned in June. In the top alliance by deal value, Ascidian Therapeutics signed an agreement with Roche for the discovery and development of RNA exon editing therapeutics targeting neurological diseases. Roche received exclusive rights to Ascidian's RNA exon editing technology for undisclosed targets. Ascidian will conduct discovery and certain preclinical activities in collaboration with Roche, which will be responsible for certain preclinical activities, and further clinical development, manufacturing, and commercialization. Ascidian will receive an up-front payment of $42m as well as up to $1.8bn in research, clinical, and commercial milestone payments, as well as sales royalties.
Formation Secures Huge Series D For AI Platform Growth
Biopharmaceutical venture capital fundraising is on the rise in 2024. In late June, Formation Bio secured a mega financing, raising $372m via a series D round led by a16z and Sanofi.
Lucid Diagnostics Seeks Clear Path To US Reimbursement For Esophageal Precancer Test
Lishan Aklog, CEO of New York-based Lucid Diagnostics, has a long-term vision to provide the paradigm of prevention-to-treatment care for esophageal cancer. In the short term, the company anticipates a favorable outcome from an upcoming pivotal Medicare assessment of its early screening technology.
Exeliom’s Bacteria-Focused Approach To Immunotherapy
In Vivo sat down with Benjamin Hadida, CEO of Exeliom, at the 2024 BIO International Convention to discuss how the company is using its first-in-class drug candidate to improve therapeutic responsiveness in immuno-oncology, immuno-inflammation and rare disease.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.